🤧 Primary Immunodeficiency Diagnostic Workup Simulator

Recognizing the Ten Warning Signs of Primary Immunodeficiency

Primary immunodeficiency diseases (PIDs) are a heterogeneous group of over 485 genetically defined disorders of immune development or function. Because early recognition dramatically improves outcomes — especially for severe combined immunodeficiency, where delayed diagnosis is fatal — the Jeffrey Modell Foundation and European Society for Immunodeficiencies (ESID) developed structured warning-sign criteria to prompt primary care providers and specialists to pursue immunologic evaluation before overwhelming infection or organ damage occurs.

• 1 in 1,200: Estimated PID prevalence (symptomatic disease; live births)
• 10: Warning signs (JMF) (≥2 present → refer for workup)
• ≥4: Infections/year threshold (new ear infections in one year)
• 5–9 yrs: Median diagnostic delay (antibody deficiencies, pre-screening era)

The Jeffrey Modell Foundation 10 warning signs

The 10 warning signs were designed as a low-specificity, high-sensitivity screening tool for primary care use. Presence of ≥2 signs should prompt referral to clinical immunology:

1. ≥4 new ear infections within 1 year 2. ≥2 serious sinus infections within 1 year 3. ≥2 months on antibiotics with little effect 4. ≥2 pneumonias within 1 year 5. Failure of an infant to gain weight or grow normally 6. Recurrent, deep skin or organ abscesses 7. Persistent thrush in mouth or fungal infection on skin, after age 1 8. Need for intravenous antibiotics to clear infections 9. ≥2 deep-seated infections (sepsis, meningitis, osteomyelitis, cellulitis) 10. A family history of PID

Additional adult-specific warning signs (ESID adaptation) include: ≥4 new infections requiring antibiotics within 1 year, recurrent infection requiring IV antibiotics, ≥2 serious sinus infections, ≥1 pneumonia per year for >1 year, chronic diarrhea with weight loss, unusual autoimmune disease, recurrent fever, and family history of PID or early death from infection.

The infection pattern triad — organism, site, and severity

Beyond simple frequency counts, three qualitative features raise suspicion for PID more than infection count alone:

Unusual organisms: infections with low-virulence or opportunistic pathogens (Pneumocystis jirovecii, Aspergillus, Burkholderia cepacia, atypical mycobacteria, disseminated BCG after vaccination) point strongly toward T-cell or phagocyte defects.

Unusual sites: recurrent deep abscesses, osteomyelitis, or infection at multiple non-contiguous sites suggests impaired containment (phagocyte or complement defects).

Unusual severity/course: infections requiring hospitalization, IV antibiotics, or that fail to resolve with standard oral therapy, plus poor growth (failure to thrive) in infancy — a hallmark of SCID — warrant urgent same-week evaluation rather than routine referral.

A single episode of Pneumocystis pneumonia, disseminated fungal infection, or failure to thrive with chronic diarrhea in an infant under 3–4 months is a pediatric immunologic emergency: it should trigger immediate lymphocyte subset flow cytometry and, where available, T-cell receptor excision circle (TREC) newborn-screening follow-up, because untreated SCID is fatal by age 1–2 without hematopoietic stem cell transplant.

First-Line Screening — CBC, Quantitative Immunoglobulins, and Lymphocyte Subsets

Once warning signs raise suspicion, tier-1 screening consists of inexpensive, widely available laboratory tests that can be ordered by a general pediatrician or internist before specialist referral. These three tests — complete blood count with differential, quantitative serum immunoglobulins, and lymphocyte subset flow cytometry — collectively identify the great majority of clinically significant PIDs and localize the defect to a broad category before functional testing begins.

• 700–1600 mg/dL: Normal IgG range (adult) (age-dependent reference)
• 70–400 mg/dL: Normal IgA range (adult) (lowest at birth, rises to age ~15)
• 40–230 mg/dL: Normal IgM range (adult) (elevated in hyper-IgM syndromes)
• 1,000–4,800/µL: Normal absolute lymphocyte count (age-dependent; infants higher)

Complete blood count and quantitative immunoglobulins

CBC with differential: • Absolute lymphocyte count (ALC) <2,500/µL in an infant is abnormal and mandates urgent T-cell subset evaluation — SCID cannot be excluded by a "normal-looking" CBC alone, since maternal engraftment can mask lymphopenia. • Neutropenia (ANC <1,500/µL) suggests congenital neutropenia syndromes (ELANE, severe congenital neutropenia); persistent neutrophilia can be seen in leukocyte adhesion deficiency (LAD), where neutrophils cannot egress from vasculature. • Eosinophilia and thrombocytopenia with small platelets suggest Wiskott-Aldrich syndrome.

Quantitative immunoglobulins (nephelometry): • IgG <2 SD below age-matched mean is the biochemical hallmark of antibody deficiency (common variable immunodeficiency, XLA, specific antibody deficiency). • Isolated IgA deficiency (IgA <7 mg/dL with normal IgG/IgM) is the most common PID overall (~1:500), usually asymptomatic but a marker for anaphylactic transfusion reaction risk. • Elevated IgM with low IgG/IgA characterizes hyper-IgM syndromes (CD40L or AID deficiency) — a class-switch recombination defect. • Elevated IgE (>2,000 IU/mL) with eczema and recurrent staphylococcal abscesses suggests hyper-IgE (Job) syndrome (STAT3 deficiency).

Lymphocyte subset flow cytometry

Flow cytometry enumerates absolute counts of T cells (CD3+, subdivided CD4+/CD8+), B cells (CD19+/CD20+), and NK cells (CD16+/CD56+), yielding a "TBNK" panel that localizes the defect before any functional assay:

• T−B+NK− pattern: X-linked SCID (IL2RG/common gamma chain) or JAK3 deficiency • T−B−NK− pattern: RAG1/RAG2 deficiency, Artemis deficiency (radiosensitive SCID) • T−B+NK+ pattern: IL7R deficiency, CD3 chain defects • T+B−NK+ pattern: XLA (BTK), autosomal recessive agammaglobulinemia • All normal counts with recurrent infection: consider phagocyte or complement defect, or antibody function defect despite normal B-cell numbers (specific antibody deficiency)

Newborn screening via T-cell receptor excision circles (TREC), now mandated in all 50 US states, detects T-cell lymphopenia (including SCID) before clinical infection onset, reducing SCID mortality from >70% to <10% with early HSCT.

Functional Testing — Vaccine Responses, Complement Activity, and Neutrophil Oxidative Burst

Quantitative labs establish that cell numbers or protein levels are abnormal, but functional testing determines whether the immune system actually works. A patient can have normal B-cell counts yet be unable to mount a protective antibody response (specific antibody deficiency), or normal neutrophil counts yet be unable to kill catalase-positive organisms (chronic granulomatous disease). These functional assays are the pivotal step that assigns the defect to one of the four major PID categories.

• ≥1.3 µg/mL: Protective pneumococcal titer (to ≥70% of serotypes tested)
• ~ 60–144 U/mL: CH50 (classical pathway) (assay-specific reference range)
• >90% stim index: DHR oxidative burst (normal) (dihydrorhodamine flow assay)
• Bimodal DHR: CGD carrier mosaic pattern (X-linked CYBB carriers)

Specific antibody response testing

Because total immunoglobulin levels can be normal despite functional antibody deficiency, specific antibody response (SAR) testing is essential:

• Pre- and post-immunization titers are drawn 4–6 weeks after vaccination with 23-valent pneumococcal polysaccharide vaccine (Pneumovax), which tests T-independent B-cell responses to polysaccharide antigen. • A protective response requires a ≥4-fold rise in titer to ≥70% of serotypes tested, reaching ≥1.3 µg/mL. • Protein antigen responses (tetanus, diphtheria toxoid) test T-dependent responses; failure here with intact polysaccharide response suggests a milder or more selective defect. • Inability to respond to polysaccharide antigens with normal protein antigen responses defines specific (polysaccharide) antibody deficiency, common in young children under age 2 (physiologic) but pathologic when persistent beyond age 4–5.

Complement pathway assays and neutrophil oxidative burst

Complement testing: • CH50 (total hemolytic complement) screens the classical pathway (C1–C9); a markedly low or absent CH50 with normal individual component repletion suggests a single complement component deficiency. • AH50 screens the alternative pathway (properdin, factor B, factor D). • Terminal complement deficiencies (C5–C9) present with recurrent Neisserial infections (meningococcemia, disseminated gonococcal infection) — a distinctive clinical clue. • Early complement deficiencies (C1q, C2, C4) present with SLE-like autoimmune disease and pyogenic sinopulmonary infections.

Neutrophil oxidative burst (dihydrorhodamine, DHR, flow cytometry assay): • Neutrophils are stimulated with phorbol myristate acetate (PMA); NADPH oxidase converts DHR to fluorescent rhodamine, measured by flow cytometry. • Absent or markedly reduced burst confirms chronic granulomatous disease (CGD) — failure of the phagocyte respiratory burst to generate superoxide, impairing killing of catalase-positive organisms (Staphylococcus aureus, Aspergillus, Burkholderia, Serratia). • X-linked CYBB-deficient carriers show a characteristic bimodal (mosaic) DHR histogram from random X-inactivation.

A child with recurrent liver, lung, or perirectal abscesses caused by catalase-positive organisms and granuloma formation on imaging should undergo DHR oxidative burst testing before extensive genetic workup — a single flow cytometry assay can essentially rule in or rule out CGD in under a day.

Targeted Gene Panels and Whole-Exome Sequencing for Molecular Diagnosis

Once the functional pattern points to a category — antibody, cellular, phagocyte, or complement — targeted next-generation sequencing panels (typically 200–450 known PID genes) or whole-exome/genome sequencing pinpoint the causative mutation. Molecular diagnosis is not academic: it dictates inheritance counseling, prognosis, eligibility for targeted or gene therapy, and — critically — whether hematopoietic stem cell transplantation is curative and urgent.

• >485: Known monogenic PID genes (IUIS 2022 classification)
• ~40–60%: Targeted panel diagnostic yield (phenotype-directed panels)
• +15–25%: WES/WGS added yield (over panel-negative cases)
• 2–6 weeks: Turnaround time (clinical NGS panel, most labs)

Panel selection strategy by functional category

Predominantly antibody deficiency category: • BTK (X-linked agammaglobulinemia) — absent peripheral B cells, profound panhypogammaglobulinemia in males • TNFRSF13B (TACI, common variable immunodeficiency) — variable penetrance, autoimmune-prone CVID subtype • CD40LG (X-linked hyper-IgM syndrome) — elevated IgM, absent IgG/IgA, Pneumocystis risk

Combined immunodeficiency / SCID category: • IL2RG (X-linked SCID, common gamma chain) — most common SCID genotype (~45% of cases) • RAG1/RAG2 (T−B−NK+ SCID, or Omenn syndrome with hypomorphic alleles) • ADA (adenosine deaminase deficiency) — metabolic SCID, enzyme replacement bridge therapy available • AIRE (autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy, APECED) — autoimmune regulator gene, chronic mucocutaneous candidiasis triad

Phagocyte defect category: • CYBB (X-linked chronic granulomatous disease, ~65% of CGD) — gp91phox subunit of NADPH oxidase • NCF1/NCF2 (autosomal recessive CGD) — p47phox/p67phox subunits • ITGB2 (leukocyte adhesion deficiency type 1) — absent CD18 integrin, delayed umbilical cord separation

Complement deficiency category: • C1QA/B/C, C2, C4A/B (early classical pathway) — lupus-like autoimmunity • C5–C9 (terminal complement/membrane attack complex) — recurrent Neisserial infection • CFH, CFI, CFB (alternative pathway regulators) — atypical hemolytic uremic syndrome, C3 glomerulopathy

Whole-exome sequencing and variant interpretation

When a targeted panel is negative but clinical suspicion remains high, whole-exome sequencing (WES) or whole-genome sequencing (WGS) with trio analysis (patient + both parents) improves diagnostic yield by identifying de novo variants, non-canonical splice variants, and genes not yet included on commercial panels.

Variant classification follows ACMG/AMP criteria (pathogenic, likely pathogenic, VUS, likely benign, benign), incorporating population frequency (gnomAD), in silico prediction, segregation with disease in family, and functional validation (e.g., confirmatory protein expression or flow cytometry for the specific gene product, such as BTK protein expression by flow cytometry in suspected XLA).

Rapid trio WES/WGS (48–96 hour turnaround) is increasingly used in critically ill neonates with suspected SCID identified on newborn TREC screening, since a confirmed molecular diagnosis accelerates transplant conditioning decisions and donor selection.

Classifying the PID and Initiating Definitive Management

The culmination of the diagnostic workup is formal classification into one of the major IUIS (International Union of Immunological Societies) categories, which directly determines the management pathway: immunoglobulin replacement for antibody deficiencies, prophylactic antimicrobials and interferon-gamma for phagocyte defects, vaccination and monitoring for complement deficiencies, or urgent hematopoietic stem cell transplantation for severe combined immunodeficiency and other life-threatening combined defects.

• 10 major groups: IUIS PID categories (2022 classification, 485+ genes)
• ≥700–1000 mg/dL: IgG replacement trough target (IVIG/SCIG maintenance)
• >90%: SCID HSCT survival (<3.5 mo) (transplanted before infection)
• ~50–70%: SCID HSCT survival (infected) (transplanted after active infection)

Management by diagnostic category

Predominantly antibody deficiency: • Immunoglobulin replacement therapy (IVIG every 3–4 weeks or subcutaneous IgG weekly) targeting trough IgG ≥700–1000 mg/dL • Prophylactic antibiotics for breakthrough sinopulmonary infection • Monitoring for bronchiectasis, autoimmune cytopenias, lymphoid malignancy (especially CVID)

Combined immunodeficiency / SCID: • Protective isolation, Pneumocystis prophylaxis (trimethoprim-sulfamethoxazole), avoidance of live vaccines • Hematopoietic stem cell transplantation (HLA-matched sibling donor preferred; matched unrelated or haploidentical alternatives) — the only curative option for most SCID genotypes • Gene therapy (autologous lentiviral-corrected CD34+ cells) now approved/available for ADA-SCID and under trial for X-linked SCID

Phagocyte defects: • Prophylactic trimethoprim-sulfamethoxazole and itraconazole (antifungal) for CGD • Interferon-gamma prophylaxis reduces serious infection frequency in CGD by ~70% • HSCT is curative and increasingly offered for severe CGD with HLA-matched donor

Complement deficiencies: • Meningococcal (including serogroup B) and pneumococcal vaccination, sometimes with prophylactic penicillin • Prompt empiric antibiotics with any fever given impaired bacterial clearance

Long-term surveillance and genetic counseling

All confirmed PID diagnoses require multidisciplinary long-term follow-up: pulmonary function monitoring for bronchiectasis, endocrine and gastrointestinal surveillance for polyautoimmunity (particularly common in CVID and APECED), and malignancy screening where risk is elevated (lymphoma in CVID and ataxia-telangiectasia, myelodysplasia in some phagocyte disorders).

Genetic counseling addresses recurrence risk (X-linked recessive: 50% of sons of carrier mothers affected; autosomal recessive: 25% recurrence for future pregnancies), availability of prenatal or preimplantation genetic testing, and cascade testing of at-risk relatives — particularly important for X-linked conditions like XLA and CGD where maternal carrier status affects future pregnancies.

Population-based TREC newborn screening for SCID, now universal across the United States, converts a historically near-uniformly fatal disease (median survival <1 year untreated) into a highly curable one when HSCT occurs before 3.5 months of age and before onset of infection — underscoring why every stage of this workup pathway is designed to compress time-to-diagnosis as much as possible.

Major PID Categories — Example Disease, Key Lab Finding, and Causative Gene